CN103919798B - 一种白癜风动物模型的构建方法 - Google Patents
一种白癜风动物模型的构建方法 Download PDFInfo
- Publication number
- CN103919798B CN103919798B CN201410116500.1A CN201410116500A CN103919798B CN 103919798 B CN103919798 B CN 103919798B CN 201410116500 A CN201410116500 A CN 201410116500A CN 103919798 B CN103919798 B CN 103919798B
- Authority
- CN
- China
- Prior art keywords
- monobenzone
- group
- cytosine
- animal model
- phosphate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 206010047642 Vitiligo Diseases 0.000 title claims abstract description 30
- 238000010171 animal model Methods 0.000 title claims abstract description 21
- 238000010276 construction Methods 0.000 title claims abstract description 12
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims abstract description 68
- 229960000990 monobenzone Drugs 0.000 claims abstract description 68
- 241000699670 Mus sp. Species 0.000 claims abstract description 59
- 239000000243 solution Substances 0.000 claims abstract description 30
- 241000699666 Mus <mouse, genus> Species 0.000 claims abstract description 24
- 229940046166 oligodeoxynucleotide Drugs 0.000 claims abstract description 22
- 238000002360 preparation method Methods 0.000 claims abstract description 11
- 238000004945 emulsification Methods 0.000 claims abstract description 9
- 239000011248 coating agent Substances 0.000 claims abstract description 8
- 238000000576 coating method Methods 0.000 claims abstract description 8
- 238000010254 subcutaneous injection Methods 0.000 claims abstract description 8
- 239000007929 subcutaneous injection Substances 0.000 claims abstract description 8
- 238000002347 injection Methods 0.000 claims abstract description 7
- 239000007924 injection Substances 0.000 claims abstract description 7
- 238000010422 painting Methods 0.000 claims abstract description 5
- 230000037396 body weight Effects 0.000 claims abstract description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 32
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 30
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 18
- 229940057995 liquid paraffin Drugs 0.000 claims description 10
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 claims description 9
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 9
- 235000021355 Stearic acid Nutrition 0.000 claims description 9
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 9
- 239000012153 distilled water Substances 0.000 claims description 9
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims description 9
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 9
- 229960003639 laurocapram Drugs 0.000 claims description 9
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 claims description 9
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 9
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 9
- 239000008117 stearic acid Substances 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 8
- 239000008346 aqueous phase Substances 0.000 claims description 6
- 238000009413 insulation Methods 0.000 claims description 6
- 239000012071 phase Substances 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims 1
- 238000002474 experimental method Methods 0.000 abstract description 17
- 238000000034 method Methods 0.000 abstract description 7
- 239000003795 chemical substances by application Substances 0.000 description 38
- 210000003491 skin Anatomy 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 14
- 210000002752 melanocyte Anatomy 0.000 description 14
- 230000003203 everyday effect Effects 0.000 description 12
- 230000008859 change Effects 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 10
- 210000001744 T-lymphocyte Anatomy 0.000 description 9
- GGXMRPUKBWXVHE-MIHLVHIWSA-N halometasone Chemical compound C1([C@@H](F)C2)=CC(=O)C(Cl)=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O GGXMRPUKBWXVHE-MIHLVHIWSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 102000004889 Interleukin-6 Human genes 0.000 description 8
- 108090001005 Interleukin-6 Proteins 0.000 description 8
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 8
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 8
- 102100040247 Tumor necrosis factor Human genes 0.000 description 8
- 238000001218 confocal laser scanning microscopy Methods 0.000 description 8
- 229960002475 halometasone Drugs 0.000 description 8
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 7
- 102100037850 Interferon gamma Human genes 0.000 description 7
- 108010074328 Interferon-gamma Proteins 0.000 description 7
- 239000000427 antigen Substances 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 206010040825 Skin depigmentation Diseases 0.000 description 6
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 102000003816 Interleukin-13 Human genes 0.000 description 5
- 108090000176 Interleukin-13 Proteins 0.000 description 5
- 229960000935 dehydrated alcohol Drugs 0.000 description 5
- 210000004207 dermis Anatomy 0.000 description 5
- 238000010820 immunofluorescence microscopy Methods 0.000 description 5
- 238000011740 C57BL/6 mouse Methods 0.000 description 4
- 229940046168 CpG oligodeoxynucleotide Drugs 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 239000000049 pigment Substances 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- 241000918728 Monotes Species 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000001994 activation Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 230000037308 hair color Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241000581650 Ivesia Species 0.000 description 2
- 206010033733 Papule Diseases 0.000 description 2
- 102000000874 Pyrin Domain-Containing 3 Protein NLR Family Human genes 0.000 description 2
- 108010001946 Pyrin Domain-Containing 3 Protein NLR Family Proteins 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000006472 autoimmune response Effects 0.000 description 2
- 238000004061 bleaching Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004624 confocal microscopy Methods 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000002780 melanosome Anatomy 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 206010040882 skin lesion Diseases 0.000 description 2
- 231100000444 skin lesion Toxicity 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- WZUVPPKBWHMQCE-XJKSGUPXSA-N (+)-haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-XJKSGUPXSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108091029430 CpG site Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Natural products C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 206010062049 Lymphocytic infiltration Diseases 0.000 description 1
- 101000889492 Mus musculus Trefoil factor 3 Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 240000005498 Setaria italica Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000004900 autophagic degradation Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 238000011281 clinical therapy Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 230000035614 depigmentation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- -1 oxygen free radical Chemical class 0.000 description 1
- 235000002252 panizo Nutrition 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410116500.1A CN103919798B (zh) | 2014-03-26 | 2014-03-26 | 一种白癜风动物模型的构建方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410116500.1A CN103919798B (zh) | 2014-03-26 | 2014-03-26 | 一种白癜风动物模型的构建方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103919798A CN103919798A (zh) | 2014-07-16 |
CN103919798B true CN103919798B (zh) | 2015-09-16 |
Family
ID=51138342
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410116500.1A Expired - Fee Related CN103919798B (zh) | 2014-03-26 | 2014-03-26 | 一种白癜风动物模型的构建方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103919798B (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106580934A (zh) * | 2015-10-16 | 2017-04-26 | 中国科学院武汉病毒研究所 | 莫诺苯宗在制备药物中的用途 |
CN105311052A (zh) * | 2015-10-23 | 2016-02-10 | 山西省中医药研究院 | 一种小鼠色素缺失动物模型的制备方法 |
CN106176262A (zh) * | 2016-06-29 | 2016-12-07 | 陕西畅想制药有限公司 | 一种新型美白祛斑化妆品及其制备方法 |
CN112806322B (zh) * | 2021-03-22 | 2022-08-16 | 石河子大学 | 一种构建色素脱失模型的方法 |
-
2014
- 2014-03-26 CN CN201410116500.1A patent/CN103919798B/zh not_active Expired - Fee Related
Non-Patent Citations (4)
Title |
---|
Effective Melanoma Immunotherapy in Mice by the Skin-Depigmenting Agent Monobenzone and the Adjuvants Imiquimod and CpG;Jasper G. van den Boorn 等;《PloS ONE》;20100531;第5卷(第5期);全文 * |
沈丹蓓 等.白癜风相关研究领域中常用的动物模型.《国外医学皮肤性病学分册》.2004,第30卷(第4期),全文. * |
祝逸平 等.局部针刺对莫诺苯宗诱导C57BL/6小鼠白癜风样模型的影响.《中华皮肤科杂志》.2014,第47卷(第1期),全文. * |
祝逸平 等.白癜风动物模型的研究进展.《国际皮肤性病学杂志》.2013,第39卷(第2期),全文. * |
Also Published As
Publication number | Publication date |
---|---|
CN103919798A (zh) | 2014-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103919798B (zh) | 一种白癜风动物模型的构建方法 | |
Feeney | Lipofuscin and melanin of human retinal pigment epithelium. Fluorescence, enzyme cytochemical, and ultrastructural studies. | |
Verma et al. | Transfollicular drug delivery: current perspectives | |
Roy et al. | Microneedle ocular patch: Fabrication, characterization, and ex-vivo evaluation using pilocarpine as model drug | |
CN101917846A (zh) | 用于皮肤伤口无疤痕愈合的多靶标RNAi治疗 | |
Mulholland et al. | Multiphoton high-resolution 3D imaging of Langerhans cells and keratinocytes in the mouse skin model adopted for epidermal powdered immunization | |
CN101969915A (zh) | 皮肤美白方法以及皮肤斑形成抑制和/或除去因子的筛选方法 | |
Tőke et al. | Exploitation of Langerhans cells for in vivo DNA vaccine delivery into the lymph nodes | |
CN103301188B (zh) | 一种苦参地龙纳米乳凝胶剂及其制备方法 | |
González-González et al. | Visualization of plasmid delivery to keratinocytes in mouse and human epidermis | |
Liu et al. | Optical reconstruction of murine colorectal mucosa at cellular resolution | |
CN104706713A (zh) | 一种治疗糖尿病溃疡的中药组合物及其制备方法 | |
Smith et al. | DNA vaccination strategy targets epidermal dendritic cells, initiating their migration and induction of a host immune response | |
CN103596594A (zh) | 自身凝胶化核酸 | |
Bassnett | Three-dimensional reconstruction of cells in the living lens: the relationship between cell length and volume | |
van der Burg et al. | A low inflammatory, Langerhans cell-targeted microprojection patch to deliver ovalbumin to the epidermis of mouse skin | |
CN104095883A (zh) | 珊瑚萃取物及其萃取方法以及其用途、珊瑚萃取物保养品 | |
CN104436159A (zh) | 一种新型滴眼液对治疗干眼的用途 | |
Watters et al. | Angiogenic effect of bioactive borate glass microfibers and beads in the hairless mouse | |
CN106265347B (zh) | 一种基于海洋生物活性物的护发组合物及其应用 | |
Tucker et al. | Assessment of DNA vaccine potential for juvenile Japanese flounder Paralichthys olivaceus, through the introduction of reporter genes by particle bombardment and histopathology | |
Volkmer-Ribeiro et al. | Freshwater sponge spicules: a new agent of ocular pathology | |
CN104818314A (zh) | 一种快速鉴定虾蟹卵母细胞核的透明液 | |
Yang et al. | Visualization of cell death in vivo during murine endotoxin-induced uveitis | |
WO2021185377A1 (zh) | 促进毛发再生的组合物、富线粒体血浆、其制造方法及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160606 Address after: 310009 West Lake Road, Zhejiang, Hangzhou, No. 38 Patentee after: Xu Aie Patentee after: Zhu Yiping Patentee after: HANGZHOU THIRD Hospital Address before: 310009 West Lake Road, Zhejiang, Hangzhou, No. 38 Patentee before: Xu Aie Patentee before: Zhu Yiping |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20170214 Address after: No. 38 Hangzhou City, Zhejiang province West Lake City Road 310014 Patentee after: HANGZHOU THIRD Hospital Address before: 310009 West Lake Road, Zhejiang, Hangzhou, No. 38 Patentee before: Xu Aie Patentee before: Zhu Yiping Patentee before: HANGZHOU THIRD Hospital |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150916 |
|
CF01 | Termination of patent right due to non-payment of annual fee |